Hospital
Hospital Development of West Phoenix INC
Hospital Development of West Phoenix INC was paid $54.34M by Medicaid between Jan 2018 and Dec 2024, across 250 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoHOSPITAL DEVELOPMENT OF WEST PHOENIX INC
GOODYEAR, AZ 85395
GOODYEAR, AZ 85395
33aNPI1093791170assigned 12/20/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$54.34M
24GClaims1,253,065
24DCodes billed250
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#10 of 78
Median peer was paid$12.21M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 214,938 | $8.32M | |
| 2019 | 220,039 | $9.65M | |
| 2020 | 170,814 | $7.57M | |
| 2021 | 189,508 | $8.20M | |
| 2022 | 173,769 | $7.51M | |
| 2023 | 159,727 | $7.07M | |
| 2024incomplete | 124,270 | $6.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 47,554 | 43,038 | $11.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 39,797 | 35,380 | $10.54M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 39,933 | 36,969 | $8.46M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 14% | 12,097 | 11,202 | $7.56M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.2% | 5,618 | 5,142 | $2.82M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.0% | 13,473 | 12,294 | $2.72M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 3.0% | 3,542 | 3,286 | $1.64M |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.9% | 5,947 | 5,478 | $1.56M |
| 72131 | 1.2% | 2,363 | 2,206 | $673K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 8,677 | 8,117 | $649K |
| G0378 | Hospital observation service, per hour | 1.0% | 19,680 | 8,932 | $554K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,616 | 11,919 | $524K |
238 more codes
| 59025 | Fetal non-stress test | <1% | 6,255 | $466K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,135 | $455K |
| 93975 | <1% | 1,444 | $389K | |
| 93971 | <1% | 2,078 | $330K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,534 | $324K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,766 | $268K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 40,536 | $261K |
| C1776 | Joint device (implantable) | <1% | 29 | $257K |
| 70486 | <1% | 1,719 | $229K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 156 | $212K |
| 70498 | <1% | 1,228 | $211K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,436 | $192K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 69 | $190K |
| 73562 | <1% | 1,619 | $156K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 192 | $123K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,262 | $97K |
| 93970 | <1% | 596 | $93K | |
| 47562 | <1% | 24 | $84K | |
| 97597 | <1% | 1,701 | $83K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,026 | $69K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 266 | $69K |
| 12001 | <1% | 754 | $54K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,408 | $43K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,045 | $40K |
| 71250 | <1% | 223 | $40K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 36,283 | $39K |
| 70496 | <1% | 927 | $39K | |
| 93798 | <1% | 705 | $39K | |
| 93458 | <1% | 14 | $33K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,321 | $31K |
| 80053 | Comprehensive metabolic panel | <1% | 67,695 | $30K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 919 | $28K |
| 76818 | <1% | 513 | $27K | |
| C1769 | Guide wire | <1% | 1,806 | $24K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 42,104 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 34,270 | $23K |
| 72128 | <1% | 1,525 | $22K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 26 | $21K |
| 74174 | <1% | 25 | $18K | |
| 96376 | <1% | 12,276 | $18K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 16,825 | $17K |
| 10060 | <1% | 299 | $15K | |
| 72100 | <1% | 652 | $15K | |
| 12002 | <1% | 272 | $13K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,374 | $13K |
| 73502 | <1% | 432 | $13K | |
| 76775 | <1% | 420 | $12K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 79,180 | $10K |
| 12011 | <1% | 144 | $10K | |
| 73130 | <1% | 1,891 | $9K | |
| 70491 | <1% | 27 | $9K | |
| 73110 | <1% | 1,356 | $9K | |
| 11043 | <1% | 52 | $9K | |
| 93976 | <1% | 2,370 | $9K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,539 | $8K |
| 76801 | <1% | 2,813 | $8K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,304 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,066 | $7K |
| 73630 | <1% | 1,917 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 9,008 | $7K |
| 84484 | <1% | 26,083 | $7K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 8,323 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,060 | $6K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 137 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,435 | $6K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 452 | $6K |
| 73030 | <1% | 2,546 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 19,298 | $5K |
| 73090 | <1% | 615 | $4K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 5,495 | $4K |
| 88342 | <1% | 522 | $4K | |
| 73564 | <1% | 1,241 | $4K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 15 | $4K |
| 64400 | <1% | 14 | $4K | |
| 83690 | <1% | 22,398 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 19,206 | $3K |
| 73590 | <1% | 813 | $3K | |
| 83735 | <1% | 30,753 | $3K | |
| 87400 | <1% | 12,142 | $3K | |
| 73610 | <1% | 1,860 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,687 | $2K |
| 74018 | <1% | 1,972 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,750 | $2K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 926 | $2K |
| 29125 | <1% | 629 | $2K | |
| 80061 | Lipid panel | <1% | 1,490 | $2K |
| 51702 | <1% | 74 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,728 | $2K |
| 81001 | <1% | 36,090 | $2K | |
| 87081 | <1% | 3,795 | $1K | |
| 0042T | <1% | 18 | $1K | |
| 73700 | <1% | 12 | $1K | |
| 84703 | <1% | 15,931 | $1K | |
| 87186 | <1% | 4,227 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,071 | $1K |
| 83880 | <1% | 5,357 | $1K | |
| 87430 | <1% | 3,938 | $1K | |
| 73080 | <1% | 764 | $1K | |
| 90715 | <1% | 2,966 | $1K | |
| 86850 | <1% | 3,385 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,121 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 31,124 | $1K |
| 85730 | <1% | 8,446 | $1K | |
| 81025 | <1% | 8,602 | $955.02 | |
| 85610 | <1% | 13,540 | $898.06 | |
| 83605 | <1% | 9,096 | $897.61 | |
| 82550 | <1% | 5,022 | $895.58 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,406 | $832.28 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,544 | $826.32 |
| J3490 | Unclassified drugs | <1% | 3,681 | $800.99 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,548 | $796.73 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 18,127 | $684.54 |
| 85379 | <1% | 4,829 | $626.51 | |
| 87088 | <1% | 13,218 | $592.94 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,474 | $572.41 |
| 82962 | <1% | 18,389 | $569.42 | |
| 81003 | <1% | 5,811 | $549.04 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,205 | $542.36 |
| 84702 | <1% | 3,922 | $476.48 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,533 | $466.94 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,217 | $460.34 |
| 73560 | <1% | 63 | $442.23 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 882 | $435.32 |
| 87040 | <1% | 3,641 | $423.55 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,592 | $352.83 |
| 76870 | <1% | 63 | $327.41 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,283 | $325.54 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,447 | $314.65 |
| 84112 | <1% | 265 | $257.57 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,738 | $227.04 |
| 72170 | <1% | 551 | $226.56 | |
| 86901 | <1% | 5,406 | $222.61 | |
| 87077 | <1% | 3,059 | $216.32 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,178 | $215.70 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 3,802 | $214.90 |
| 87420 | <1% | 1,735 | $202.80 | |
| 29505 | <1% | 38 | $192.22 | |
| 85027 | <1% | 5,147 | $181.73 | |
| 97162 | <1% | 941 | $178.93 | |
| 86900 | <1% | 5,410 | $170.30 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,011 | $156.38 |
| 87631 | <1% | 68 | $125.90 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,529 | $125.47 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,658 | $119.72 |
| 82803 | <1% | 53 | $112.26 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,100 | $110.70 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,488 | $107.66 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,273 | $103.56 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,388 | $101.21 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,530 | $100.92 |
| A9270 | Non-covered item or service | <1% | 12,985 | $99.33 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,651 | $92.01 |
| 87210 | <1% | 1,976 | $90.34 | |
| 97166 | <1% | 411 | $79.68 | |
| 84145 | <1% | 110 | $77.27 | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,701 | $71.34 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,583 | $61.92 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,662 | $60.26 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 365 | $59.28 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,047 | $54.10 |
| 84100 | <1% | 1,561 | $48.09 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,524 | $46.44 |
| 82009 | <1% | 1,717 | $44.85 | |
| 88304 | <1% | 980 | $43.72 | |
| 97167 | <1% | 47 | $40.42 | |
| 72040 | <1% | 68 | $37.27 | |
| 87205 | <1% | 819 | $34.64 | |
| 96367 | <1% | 385 | $31.05 | |
| G0008 | Administration of influenza virus vaccine | <1% | 302 | $30.40 |
| 83615 | <1% | 244 | $27.84 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 115 | $27.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 44 | $25.00 |
| 90686 | <1% | 228 | $24.04 | |
| 82570 | <1% | 314 | $20.53 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 190 | $18.39 |
| 85651 | <1% | 374 | $17.37 | |
| 97116 | <1% | 568 | $17.28 | |
| 94760 | <1% | 261 | $16.53 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 860 | $15.72 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 58 | $15.51 |
| 86141 | <1% | 244 | $15.50 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,190 | $15.11 |
| 87147 | <1% | 1,117 | $13.08 | |
| 87070 | <1% | 728 | $11.37 | |
| 90674 | <1% | 110 | $11.13 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,294 | $10.72 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 259 | $10.50 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 162 | $7.50 |
| 84156 | <1% | 173 | $3.26 | |
| 82270 | <1% | 90 | $0.80 | |
| J1815 | Injection, insulin, per 5 units | 0% | 1,882 | $0.00 |
| A9150 | Non-prescription drugs | 0% | 271 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 452 | $0.00 |
| 89060 | 0% | 257 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 110 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 128 | $0.00 |
| J3590 | Unclassified biologics | 0% | 29 | $0.00 |
| 82150 | 0% | 14 | $0.00 | |
| 96368 | 0% | 112 | $0.00 | |
| 74420 | 0% | 119 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 198 | $0.00 |
| 88307 | 0% | 27 | $0.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 17 | $0.00 |
| 71101 | 0% | 72 | $0.00 | |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 108 | $0.00 |
| 82360 | 0% | 15 | $0.00 | |
| 85018 | 0% | 15 | $0.00 | |
| 73060 | 0% | 32 | $0.00 | |
| 51798 | 0% | 27 | $0.00 | |
| 74022 | 0% | 41 | $0.00 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 15 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 14 | $0.00 |
| 73552 | 0% | 16 | $0.00 | |
| 97165 | 0% | 28 | $0.00 | |
| 74019 | 0% | 12 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 601 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 556 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 929 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 360 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 342 | $0.00 |
| 80076 | 0% | 180 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 26 | $0.00 |
| 84550 | 0% | 155 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 40 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 106 | $0.00 |
| 82731 | 0% | 49 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 165 | $0.00 |
| 93017 | 0% | 26 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 44 | $0.00 |
| 76937 | 0% | 86 | $0.00 | |
| 29515 | 0% | 62 | $0.00 | |
| 73140 | 0% | 26 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 82 | $0.00 |
| 93880 | 0% | 27 | $0.00 | |
| 97163 | 0% | 12 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 12 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 75 | $0.00 |
| 84439 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialORONA, JENNIFER (CFO)
| Provider | Location | Paid |
|---|---|---|
| Hospital Development of West Phoenix INC | Buckeye, AZ | $16.72M |
| Hospital Development of West Phoenix INC | Goodyear, AZ | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.